Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Biomarkers for Predicting the Outcome of Various Cancer Immunotherapies Publisher Pubmed



Jafarzadeh L1 ; Khakpoorkoosheh M1 ; Mirzaei H2 ; Mirzaei HR1
Authors

Source: Critical Reviews in Oncology/Hematology Published:2021


Abstract

Cancer immunotherapy has appeared as a well-known therapeutic modality for different cancers. Yet, only a subset of patients derive clinical benefit. It is thus critical to understand the determinants driving response, resistance and adverse effects.Predictive biomarkers in different modalities of cancer immunotherapy offer novel information about the effect of a therapeutic intervention. These biomarkers and their patterns may not only operate similarly across different tumor types that are amenable to these therapies but also assist to identify patients who will benefit from the treatment and subsequently leading to tailored immunotherapy with the wider-successfully-targeted patient population. In this review, we will outline a variety of predictive biomarkers in various cancer immunotherapies and their clinical utility. It is anticipated that the incorporation of biomarker studies in the clinical practice will help optimize therapeutic decision making and realize the potential clinical benefit of biomarker-guided therapy. © 2020 Elsevier B.V.
Related Docs
View other Related Docs
1. Biomarkers for Immune Checkpoint Inhibitors, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
2. Tumor Immunology, Clinical Immunology (2022)
3. Immunotherapy of Cancers Comes of Age, Expert Review of Clinical Immunology (2017)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (11)
Seyed Hamidollah Ghaffari (2)
Other Related Docs
4. Resistance to Immunotherapy in Human Malignancies: Mechanisms, Research Progresses, Challenges, and Opportunities, Journal of Cellular Physiology (2022)
5. Pd-1/Pd-L1 Pathway: Basic Biology and Role in Cancer Immunotherapy, Journal of Cellular Physiology (2019)
6. Predictive and Therapeutic Biomarkers in Chimeric Antigen Receptor T-Cell Therapy: A Clinical Perspective, Journal of Cellular Physiology (2019)
7. Review of the Recent Clinical Trials for Pd-1/Pd-L1 Based Lung Cancer Immunotherapy, Expert Review of Anticancer Therapy (2021)
8. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)
9. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)
10. The Evolving Landscape of Predictive Biomarkers in Immuno-Oncology With a Focus on Spatial Technologies, Clinical and Translational Immunology (2020)
11. Cancer Immunotherapy Confers a Global Benefit, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
12. Immunotherapeutic Targets in Non-Small Cell Lung Cancer, Immunology (2023)
13. Understanding the Tumor Microenvironment for Effective Immunotherapy, Medicinal Research Reviews (2021)
14. Hurdles in Cancer Immunotherapy, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
15. Recent Advances in Immune Checkpoint Therapy in Non-Small Cell Lung Cancer and Opportunities for Nanoparticle-Based Therapy, European Journal of Pharmacology (2021)
16. Cancer Immunology, Encyclopedia of Infection and Immunity (2022)
17. Recent Progress in Cancer Immunotherapy: Overview of Current Status and Challenges, Pathology Research and Practice (2023)
18. Pd-1 and Cancer: Molecular Mechanisms and Polymorphisms, Immunogenetics (2018)
19. Resistance Mechanisms to Programmed Cell Death Protein 1 and Programmed Death Ligand 1 Inhibitors, Expert Opinion on Biological Therapy (2021)
20. Tumor Immunotherapies by Immune Checkpoint Inhibitors (Icis); the Pros and Cons, Cell Communication and Signaling (2022)